<DOC>
	<DOCNO>NCT00500370</DOCNO>
	<brief_summary>This multicenter study design compare effect exenatide plus lifestyle modification plan versus placebo plus lifestyle modification plan weight loss non-diabetic , obese subject .</brief_summary>
	<brief_title>A Pilot Study Effects Exenatide Body Weight Non-Diabetic , Obese Patients</brief_title>
	<detailed_description />
	<mesh_term>Body Weight</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Have Body Mass Index ( BMI ) &gt; = 30kg/m^2 Have ever participate study previously , study use exenatide ( AC2993/LY2148568 ) GLP1 analog Have participate interventional medical , surgical , pharmaceutical study ( study experimental , drug , medical , surgical treatment give ) within 30 day study start ( criterion include drug receive regulatory approval indication time study entry ) Diagnosis diabetes mellitus ( gestational diabetes ) , previous use antidiabetic medication &gt; 3 month Have change prescribe lipidlowering blood pressure agent within 4 week screen Used drug weight loss ( e.g. , Xenical [ orlistat ] , Meridia [ sibutramine ] , Acutrim [ phenylpropanolamine ] , Accomplia [ rimonabant ] , Alli [ lowdose orlistat ] , similar overthecounter weight loss remedy medication ) within 3 month screen Are actively participate , participate formal weight loss program within last 3 month Have history chronic use drug directly affect gastrointestinal motility , include , limited Reglan ( metoclopramide ) chronic macrolide antibiotic Have treat antidiabetic medication within 3 month screen Are receive chronic ( lasting longer 2 week ) systemic glucocorticoid therapy receive therapy within 4 week immediately prior study start Have bariatric surgery Have organ transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>exenatide</keyword>
	<keyword>obesity</keyword>
	<keyword>diabetes</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
</DOC>